High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status:
Recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This study will determine whether the presence of DNA repair deficiency in the form of
alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to
the use of intermittent high dose testosterone. This therapy may result in responses in
tumors which are genetically unstable because of DNA repair deficiency and this is a
prospective study to test that hypothesis